Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials

This article demonstrates the use of two plots to better support investigators to assimilate large volumes of adverse events data in randomised controlled trials. It examines the value of the use a plot provides in two trials- Remdesivir for COVID-19 and GDNF for Parkinson’s disease. It demonstrated that asymmetry in the volcano plot can flag extreme events that are less obvious from review of frequency tables, and the dot plot provides a more comprehensive representation by means of a more detailed summary.